WuXi PharmaTech (WX) Misses Q2 EPS by 1c, Reconfirms FY Rev Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
WuXi PharmaTech Announces Second-Quarter 2015 Results
August 13, 2015 4:30 PM EDTSHANGHAI, Aug. 13, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc.("WuXi") (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the second quarter of 2015.Â
Second-Quarter 2015 Highlights
Net Revenues Increased 18.8% Year Over Year to $194.1 Million Net Revenues for Laboratory Services Grew 17.9% Year Over Year to $123.5 Million Net Revenues for Small-Molecule Manufacturing Services Increased 10.0% Year Over Year to $45.9 Million Net... More